State Street’s iTeos Therapeutics ITOS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-594,555
Closed -$5.93M 4334
2025
Q2
$5.93M Buy
594,555
+12,558
+2% +$101K ﹤0.01% 2857
2025
Q1
$3.47M Sell
581,997
-3,939
-0.7% -$28.9K ﹤0.01% 3030
2024
Q4
$4.5M Sell
585,936
-589,417
-50% -$5.06M ﹤0.01% 3021
2024
Q3
$12M Buy
1,175,353
+211,452
+22% +$3.23M ﹤0.01% 2500
2024
Q2
$14.3M Buy
963,901
+386,356
+67% +$5.54M ﹤0.01% 2342
2024
Q1
$7.88M Buy
577,545
+25,990
+5% +$283K ﹤0.01% 2716
2023
Q4
$6.04M Sell
551,555
-1,029,938
-65% -$10.2M ﹤0.01% 2859
2023
Q3
$17.3M Buy
1,581,493
+16,291
+1% +$208K ﹤0.01% 2249
2023
Q2
$20.7M Sell
1,565,202
-262,189
-14% -$3.74M ﹤0.01% 2229
2023
Q1
$24.9M Buy
1,827,391
+90,101
+5% +$1.61M ﹤0.01% 2081
2022
Q4
$33.9M Sell
1,737,290
-370,578
-18% -$7.24M ﹤0.01% 1894
2022
Q3
$40.2M Sell
2,107,868
-370,464
-15% -$8.53M ﹤0.01% 1757
2022
Q2
$51.1M Buy
2,478,332
+766,441
+45% +$18.2M ﹤0.01% 1620
2022
Q1
$55.1M Buy
1,711,891
+948,540
+124% +$34.5M ﹤0.01% 1692
2021
Q4
$35.5M Buy
763,351
+441,244
+137% +$14.7M ﹤0.01% 2057
2021
Q3
$8.7M Buy
322,107
+3,938
+1% +$103K ﹤0.01% 2963
2021
Q2
$8.16M Sell
318,169
-384,841
-55% -$9.17M ﹤0.01% 3016
2021
Q1
$24M Buy
703,010
+514,008
+272% +$18.6M ﹤0.01% 2250
2020
Q4
$6.39M Buy
189,002
+57,773
+44% +$1.53M ﹤0.01% 2845
2020
Q3
$3.24M Buy
+131,229
New +$3.53M ﹤0.01% 3002

Other funds holding ITOS

State Street's ITOS Position: Q3 2025 in Review

State Street sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 594,555 shares — an estimated $5.93M sold.

State Street first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $55.1M in Q1 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

  • State Street reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • State Street sold 594,555 iTeos Therapeutics shares in Q3 2025, an estimated $5.93M.
  • State Street first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
  • State Street's iTeos Therapeutics position peaked at $55.1M in Q1 2022.
  • 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on State Street's 13F filing for Q3 2025, filed 14 Nov 2025.